Oral bioavailability of phenobarbital: a comparison of a solution in Myvacet 9-08, a suspension, and a tablet.
OBJECTIVE
A three-way crossover study with seven healthy male volunteers was conducted to determine the relative bioavailability of phenobarbital after single dose administration of 100 mg of phenobarbital as oral solution in Myvacet 9-08, and as a suspension, compared with a 100 mg phenobarbital tablet.


METHODS
At 4-week intervals each subject received the solution in Myvacet 9-08, the suspension and the tablet in randomized order. Blood samples were collected for 48 h after each dose for analysis of phenobarbital. From the individual serum concentration-versus-time curves Cmax and Tmax were determined and AUC0-48 was calculated.


RESULTS
All three oral dosage forms of phenobarbital are bioequivalent. No significant differences in Tmax were observed.


CONCLUSIONS
The oral solution in Myvacet 9-08, and the suspension of phenobarbital proved to be bioequivalent to a tablet.
Yska
J P
JP
Department of Clinical Pharmacy, Rijnstate Hospital, Arnhem, The Netherlands. yskajp@mcz-nw.znb.nl
Essink
G W
GW
Bosch
F H
FH
Lankhaar
G
G
van Sorge
A A
AA
D000328:Adult; D019540:Area Under Curve; D001682:Biological Availability; D002851:Chromatography, High Pressure Liquid; D018592:Cross-Over Studies; D006801:Humans; D006993:Hypnotics and Sedatives / Q000008:administration & dosage / Q000493:pharmacokinetics*; D008297:Male; D008875:Middle Aged; D010634:Phenobarbital / Q000008:administration & dosage / Q000493:pharmacokinetics*; D018401:Sample Size; D013056:Spectrophotometry, Ultraviolet; D013535:Suspensions; D013607:Tablets; D013810:Therapeutic Equivalency
D006993:Hypnotics and Sedatives; D013535:Suspensions; D013607:Tablets; D010634:Phenobarbital